All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Salvage lenalidomide in four rare oncological diseases

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F13%3A%230002125" target="_blank" >RIV/65269705:_____/13:#0002125 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/13:00065660 RIV/00209805:_____/13:#0000476

  • Result on the web

    <a href="http://dx.doi.org/10.1700/1377.15326" target="_blank" >http://dx.doi.org/10.1700/1377.15326</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1700/1377.15326" target="_blank" >10.1700/1377.15326</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Salvage lenalidomide in four rare oncological diseases

  • Original language description

    In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-daycycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxygluc

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Tumori

  • ISSN

    0300-8916

  • e-ISSN

  • Volume of the periodical

    99

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    IT - ITALY

  • Number of pages

    6

  • Pages from-to

    "e251"-"e256"

  • UT code for WoS article

  • EID of the result in the Scopus database